SciClone Pharmaceuticals, Inc. - Product Pipeline Review - Q4 2010

Date: November 1, 2010
Pages: 47
Price:
US$ 500.00 US$ 450.00
Offer valid until December 31, 2014!
License [?]:
Publisher: Global Markets Direct
Report type: Company Report
Delivery: E-mail Delivery (PDF)
ID: SE96469E5C2EN
Leaflet:

Download PDF Leaflet

SciClone Pharmaceuticals, Inc. – Product Pipeline Review – Q4 2010

Summary

Global Market Direct’s pharmaceuticals report, “SciClone Pharmaceuticals, Inc. – Product Pipeline Review – Q4 2010” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope
  • SciClone Pharmaceuticals, Inc. – Brief company overview including business description, key information and facts, and its locations and subsidiaries.
  • Review of current pipeline of SciClone Pharmaceuticals, Inc. human therapeutic division.
  • Overview of pipeline therapeutics across various therapy areas.
  • Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
  • Product profiles for late stage and clinical stage products of SciClone Pharmaceuticals, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
  • Recent updates of the SciClone Pharmaceuticals, Inc.’s pipeline in the last quarter.
  • Key discontinued and dormant projects.
  • Latest news and deals relating to the products.

Reasons to buy
  • Evaluate SciClone Pharmaceuticals, Inc.’s strategic position with total access to detailed information on its product pipeline.
  • Assess the growth potential of SciClone Pharmaceuticals, Inc. in its therapy areas of focus.
  • Identify new drug targets and therapeutic classes in the SciClone Pharmaceuticals, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
  • Exploit collaboration and partnership opportunities with SciClone Pharmaceuticals, Inc..
  • Avoid Intellectual Property Rights related issues.
  • Explore the dormant and discontinued projects of SciClone Pharmaceuticals, Inc. and identify potential opportunities in those areas.
SciClone Pharmaceuticals, Inc. Snapshot
SciClone Pharmaceuticals, Inc. Overview
Key Information
Key Facts
SciClone Pharmaceuticals, Inc. – Research and Development Overview
Key Therapeutic Areas
SciClone Pharmaceuticals, Inc. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
SciClone Pharmaceuticals, Inc. – Pipeline Products Glance
SciClone Pharmaceuticals, Inc. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
SciClone Pharmaceuticals, Inc. – Drug Profiles
RP101 + Gemcitabine
  Product Description
  Mechanism of Action
  R&D Progress
SCV-07
  Product Description
  Mechanism of Action
  R&D Progress
SCV-07 + Ribavirin
  Product Description
  Mechanism of Action
  R&D Progress
SciClone Pharmaceuticals, Inc. – Pipeline Analysis
SciClone Pharmaceuticals, Inc. – Pipeline Products by Therapeutic Class
SciClone Pharmaceuticals, Inc. Pipeline Products By Target
SciClone Pharmaceuticals, Inc. – Recent Pipeline Updates
SciClone Pharmaceuticals, Inc. - Dormant Projects
SciClone Pharmaceuticals, Inc. – Company Statement
SciClone Pharmaceuticals, Inc. – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
Sep 29, 2010: SciClone Identifies Unique Genetic Markers Associated With Patient Response To SCV-07 Treatment In Oral Mucositis
Jun 30, 2010: SciClone And Sigma-Tau Report Final Data From Clinical Trial Of ZADAXIN As H1N1 Vaccine Enhancer
May 17, 2010: SciClone Provides Further Topline Results From Phase II Study Of SCV-07 For Prevention Of Oral Mucositis
May 17, 2010: SciClone Provides Further Topline Results From Phase II Study Of SCV-07 For Prevention Of Oral Mucositis
Mar 30, 2010: SciClone Announces Topline Results From Phase II Clinical Trial Of SCV-07 For Prevention Of Oral Mucositis
Mar 24, 2010: SciClone Receives European Approval For Ondansetron RapidFilm To Treat Nausea And Vomiting
Feb 08, 2010: SciClone And Sigma-Tau Announce Additional Positive Results In Clinical Study Examining ZADAXIN's Ability To Enhance Response To H1N1 Vaccine
Feb 08, 2010: SciClone And Sigma-Tau Announce Additional Positive Results In Clinical Study Examining ZADAXIN's Ability To Enhance Response To H1N1 Vaccine
Jan 12, 2010: Sciclone Pharmaceuticals And Sigma-Tau Announce Positive Results In Clinical Study Examining Of ZADAXIN
Nov 30, 2009: SciClone Announces Commencement And Complete Enrollment Of Clinical Study Examining Zadaxin’s Ability To Enhance The H1N1 Vaccine
Financial Deals Landscape
SciClone Pharmaceuticals, Inc., Deals Volume Summary, 2004 to YTD 2010
SciClone Pharmaceuticals, Inc., Deals Summary By Region, 2004 to YTD 2010
SciClone Pharmaceuticals, Inc., Deals Summary, 2004 to YTD 2010
SciClone Pharmaceuticals, Inc. Detailed Deal Summary
SciClone Pharmaceuticals Enters Into Co-Development Agreement With Nektar Therapeutics
Licensing Agreements
SciClone Pharmaceuticals Enters Into Licensing Agreement With APR Applied Pharma
SciClone Enteres Into Licensing Agreement With Resistys
SciClone Enteres Into Agreement With Biocomaptibles
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer 47

LIST OF TABLES

SciClone Pharmaceuticals, Inc. – Pipeline by Therapy Area and Indication, 2010
SciClone Pharmaceuticals, Inc. – Pipeline by Stage of Development, 2010
SciClone Pharmaceuticals, Inc. – Monotherapy Products in Pipeline, 2010
SciClone Pharmaceuticals, Inc. – Combination Treatment Modalities in Pipeline, 2010
SciClone Pharmaceuticals, Inc. - Phase II, 2010
SciClone Pharmaceuticals, Inc. - Pipeline By Therapeutic Class, 2010
SciClone Pharmaceuticals, Inc. - Pipeline By Target, 2010
SciClone Pharmaceuticals, Inc. – Recent Pipeline Updates, 2010
SciClone Pharmaceuticals, Inc. - Dormant Developmental Projects, 2010
SciClone Pharmaceuticals, Inc., Subsidiaries
SciClone Pharmaceuticals, Inc., Deals Summary, 2004 to YTD 2010
SciClone Pharmaceuticals, Inc., Deals Summary by Region, 2004 to YTD 2010
SciClone Pharmaceuticals, Inc., Deals Summary, 2004 to YTD 2010
SciClone Pharmaceuticals Enters Into Co-Development Agreement With Nektar Therapeutics
SciClone Pharmaceuticals Enters Into Licensing Agreement With APR Applied Pharma
SciClone Enteres Into Licensing Agreement With Resistys
SciClone Enteres Into Agreement With Biocomaptibles 45

LIST OF FIGURES

SciClone Pharmaceuticals, Inc. – Pipeline by Therapy Area and Indication, 2010
SciClone Pharmaceuticals, Inc. – Pipeline by Stage of Development, 2010
SciClone Pharmaceuticals, Inc. – Monotherapy Products in Pipeline, 2010
SciClone Pharmaceuticals, Inc. – Combination Treatment Modalities in Pipeline, 2010
SciClone Pharmaceuticals, Inc. – Pipeline By Therapeutic Class, 2010
SciClone Pharmaceuticals, Inc. - Pipeline By Target, 2010 19

Ask Your Question

SciClone Pharmaceuticals, Inc. - Product Pipeline Review - Q4 2010
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry: